BioVie Inc.

OTCQB Podcast

English - August 29, 2017 18:45 - 4 minutes - 4.29 MB - ★★★★ - 9 ratings
Investing Business otcmarketsgroup otcqb venturemarket Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Signal Bay, Inc.

Next Episode: Ener-Core, Inc.

100,000 patients in the U.S. have ascites due to advanced liver cirrhosis, with no approved drug to treat ascites. Jonathan Adams, CEO & CFO of BioVie Inc. (OTCQB: BIVI) discusses how the company is developing what they hope to be the first ever approved drug to treat ascites.